Bruker (BRKR) announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays. Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gernot Wolfram. With more than 40 years of experience, RECIPE is a highly respected, profitable company with 2024 revenues of more than $15M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker Corporation: Strategic Positioning and Growth Prospects Drive Buy Rating
- China raises tariffs on U.S. goods, banks report Q1 results: Morning Buzz
- Morning Movers: Banks up slightly after first quarter earnings
- Bruker reports preliminary Q1 revenue $795M-$800M, consensus $757.03M
- Bruker price target lowered to $50 from $60 at Barclays